- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07858643
A Study of LDGraft In Single Level Lumbar Interbody Fusion (AMBITION)
The objective of the study is to evaluate the safety and effectiveness of LDGraft (investigational device) when applied in a lumbar interbody fusion procedure in the treatment of patients with lumbar Degenerative Disc Disease (DDD).
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Robyn Cochrane
- Telefoonnummer: +44115 7738447
- E-mail: rcochrane@locatebio.com
Studie Locaties
-
-
-
Tbilisi, Georgië, 44600
- Werving
- West Georgia Medical Center
-
Contact:
- Study Coordinator
-
Tbilisi, Georgië, 4600
- Werving
- JSC Georgian Clinics Kutaisi Referral Hospital
-
Contact:
- Study Coordinator
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Skeletally mature adults ≥22 and ≤80 years at the time of surgery
- Willing and able to give written informed consent and comply with study protocol and postoperative management program
- Degenerative disc disease of the lumbosacral spine in one level requiring fusion confirmed by patient history and radiographic imaging
- Preoperative Oswestry Disability Index score ≥ 35
- Participant has not responded to conservative treatment (e.g. medications, injections, physical therapy, etc.) for a period of 6 months
Exclusion Criteria:
- Previous lumbar spine instrumentation (i.e., anterior disc replacement, interspinous device) or a previous interbody fusion procedure in the lumbar spine
- More than one level lumbar spine level requiring fusion
- Three or more contiguous lumbar spine levels requiring decompression
- Known hypersensitivity or allergy to any components of the study treatments inclusive of hypersensitivity or allergy to any BMP-2 type recombinant proteins or peptides.
- Pregnant, planning to become pregnant during the follow-up time period, or breast-feeding women
- Presence of active malignancy
- Requires bone growth stimulation in the lumbar spine
- Active local or systemic infection
- Spondylolisthesis greater than Grade 2 (50% translation)
- Currently smoking or using nicotine products, including e-cigarette products (e.g., vaping)
- Any degenerative muscular or neurological condition that would interfere with evaluation of outcomes, including but not limited to Parkinson's disease, amyotrophic lateral sclerosis (ALS), or multiple sclerosis
- Any medical condition requiring treatment with any drug known to potentially interfere with bone/soft tissue healing or receiving radiation therapy that is expected to continue for the duration of the study
- Body Mass Index > 40
- Insulin-dependent diabetes mellitus
- Osteopenia or osteoporosis of the spine
- Any secondary causes of osteoporosis or other conditions known to adversely affect osteogenesis
- Participation in another investigational study within 30 days prior to surgery for investigational devices, or within the last three months for investigational drugs
- Current or recent history of chemical/alcohol abuse or dependency using standard medical definition of DSM-5 code
- In the opinion of the investigator, the participant has a behavioral, cognitive, social or medical problem that may interfere with the assessment of the safety or effectiveness of the product
- Radiographically compromised vertebral bodies at the index level due to current or past trauma
- Currently a prisoner
- Involved in active litigation relating to his/her spinal condition or workers compensation claimants.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: LDGraft
|
LDGraft (b-TCP / rhBMP-2) bone graft substitute |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Secondary Surgical Intervention (SSI)
Tijdsspanne: 6-month and 12-month follow up
|
No index level secondary surgical intervention reported |
6-month and 12-month follow up
|
|
Radiographic Fusion
Tijdsspanne: 6-month and 12-month follow up
|
Radiographic fusion derived from bridging bone, angular motion and translational motion assessment via CT |
6-month and 12-month follow up
|
|
Oswestry Disability Index (ODI) Improvement
Tijdsspanne: 6-month and 12-month follow up
|
At least 15 point improvement in ODI compared to baseline |
6-month and 12-month follow up
|
|
No new or worsening lumbar spine neurological condition
Tijdsspanne: 6-month and 12-month follow up
|
No new or worsening lumbar spine neurological condition compared to baseline |
6-month and 12-month follow up
|
|
No Serious Device Related Adverse Events
Tijdsspanne: 6-month and 12-month follow up
|
6-month and 12-month follow up
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Visual Analog Score (VAS) Leg Improvement
Tijdsspanne: 6-week, 3-month, 6-month and 12-month follow up
|
20mm improvement compared to baseline |
6-week, 3-month, 6-month and 12-month follow up
|
|
Visual Analog Score (VAS) Back Improvement
Tijdsspanne: 6-week, 3-month, 6-month and 12-month follow up
|
20mm improvement compared to baseline |
6-week, 3-month, 6-month and 12-month follow up
|
|
Oswestry Disability Index (ODI) Change
Tijdsspanne: 6-week, 3-month, 6-month and 12 month follow up
|
Mean change over time intervals |
6-week, 3-month, 6-month and 12 month follow up
|
|
Visual Analog Score (VAS) Leg Change
Tijdsspanne: 6-week, 3-month, 6-month and 12-month follow up
|
Mean change over time intervals |
6-week, 3-month, 6-month and 12-month follow up
|
|
Visual Analog Score (VAS) Back Change
Tijdsspanne: 6-week, 3-month, 6-month and 12-month follow up
|
Mean change over time intervals |
6-week, 3-month, 6-month and 12-month follow up
|
|
Quality of Life & Satisfaction
Tijdsspanne: 6-week, 3-month-, 6-month and 12-month follow up
|
Evaluation of Quality of Life & Satisfaction survey results |
6-week, 3-month-, 6-month and 12-month follow up
|
|
Radiogrpahic Outcomes
Tijdsspanne: 6-week, 3-month, 6-month and 12-month follow up
|
Radiographic outcomes as defined by Image Review Charter |
6-week, 3-month, 6-month and 12-month follow up
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- CI-002
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .